Mikhail Shtivelband

3.0k total citations · 1 hit paper
35 papers, 1.3k citations indexed

About

Mikhail Shtivelband is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Mikhail Shtivelband has authored 35 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 10 papers in Genetics. Recurrent topics in Mikhail Shtivelband's work include Cancer Treatment and Pharmacology (10 papers), Advanced Breast Cancer Therapies (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Mikhail Shtivelband is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Advanced Breast Cancer Therapies (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). Mikhail Shtivelband collaborates with scholars based in United States, France and Japan. Mikhail Shtivelband's co-authors include Mario Campone, Martine Piccart, Gabriel N. Hortobágyi, Shinzaburo Noguchi, Alejandra Perez, Ines Deleu, Louise Provencher, Howard A. Burris, Hope S. Rugo and José Baselga and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Mikhail Shtivelband

35 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

2014 407 citations Martine Piccart, Gabriel N. Hortobágyi et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mikhail Shtivelband United States	15	737	709	477	323	166	35	1.3k
Angelica Fasolo Italy	18	856 1.2×	390 0.6×	674 1.4×	284 0.9×	105 0.6×	43	1.5k
Zhenfan Yang China	19	1.1k 1.5×	1.2k 1.7×	549 1.2×	308 1.0×	128 0.8×	39	1.8k
Erin Macrae United States	13	708 1.0×	445 0.6×	250 0.5×	360 1.1×	82 0.5×	20	1.0k
Luigi Formisano Italy	25	1.1k 1.5×	772 1.1×	1.1k 2.4×	494 1.5×	236 1.4×	73	2.2k
Haruhiro Yukiue Japan	29	812 1.1×	1.1k 1.5×	839 1.8×	352 1.1×	66 0.4×	71	2.0k
Karen G. Montgomery Australia	15	528 0.7×	397 0.6×	1.1k 2.4×	362 1.1×	188 1.1×	17	1.6k
Katherine E. Hutchinson United States	19	920 1.2×	536 0.8×	972 2.0×	595 1.8×	180 1.1×	48	1.8k
Timothy Pluard United States	20	1.3k 1.8×	751 1.1×	534 1.1×	772 2.4×	165 1.0×	80	1.9k
Heidi Savage United States	12	731 1.0×	389 0.5×	801 1.7×	489 1.5×	138 0.8×	23	1.4k
Rosa Caputo Italy	20	1.3k 1.8×	906 1.3×	1.0k 2.2×	355 1.1×	135 0.8×	21	2.3k

Countries citing papers authored by Mikhail Shtivelband

Since Specialization

Citations

This map shows the geographic impact of Mikhail Shtivelband's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mikhail Shtivelband with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mikhail Shtivelband more than expected).

Fields of papers citing papers by Mikhail Shtivelband

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mikhail Shtivelband. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mikhail Shtivelband. The network helps show where Mikhail Shtivelband may publish in the future.

Co-authorship network of co-authors of Mikhail Shtivelband

This figure shows the co-authorship network connecting the top 25 collaborators of Mikhail Shtivelband. A scholar is included among the top collaborators of Mikhail Shtivelband based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mikhail Shtivelband. Mikhail Shtivelband is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Robinson, Clifford G., Ligang Xing, Hiroshi Tanaka, et al.. (2023). Phase 3 study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG3515).. Journal of Clinical Oncology. 41(16_suppl). TPS8607–TPS8607. 5 indexed citations

Robinson, Clifford G., Lijie Xing, Shahed N. Badiyan, et al.. (2022). 122TiP Phase III study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG 3515). Annals of Oncology. 33. S88–S88. 3 indexed citations

Sharman, Jeff P., Danielle M. Brander, Anthony R. Mato, et al.. (2021). Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. The Lancet Haematology. 8(4). e254–e266. 39 indexed citations

Yardley, Denise A., Rob Coleman, Pierfranco Conté, et al.. (2018). nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology. 29(8). 1763–1770. 91 indexed citations

Reck, Martin, Tom C. Karagiannis, Thomas Wehler, et al.. (2018). Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC).. Journal of Clinical Oncology. 36(15_suppl). 9047–9047. 10 indexed citations

Yardley, Denise A., Robert L. Coleman, Pierfranco Conté, et al.. (2017). Abstract P5-15-03: nab-paclitaxel + carboplatin or gemcitabine vs gemcitabine/carboplatin as first-line treatment for patients with triple-negative metastatic breast cancer: Results from the randomized phase 2 portion of the tnAcity trial. Cancer Research. 77(4_Supplement). P5–15. 9 indexed citations

Martín, Miguel, Luc Dirix, Joyce O’Shaughnessy, et al.. (2016). A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4). Annals of Oncology. 28(2). 313–320. 136 indexed citations

Gerber, David E., David R. Spigel, Mikhail Shtivelband, et al.. (2016). Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 17(3). 169–176. 16 indexed citations

Planchard, David, Mikhail Shtivelband, Kelvin Shi, et al.. (2015). A phase III study of MEDI4736 (M), an anti-PD-L1 antibody, in monotherapy or in combination with Tremelimumab (T), versus standard of care (SOC) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who have received at least two prior systemic treatment regimens (ARCTIC).. Journal of Clinical Oncology. 33(15_suppl). TPS8104–TPS8104. 9 indexed citations

10.

Ramalingam, Suresh S., Pasi A. Jänne, Tony Mok, et al.. (2014). Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. The Lancet Oncology. 15(12). 1369–1378. 111 indexed citations

11.

Piccart, Martine, Gabriel N. Hortobágyi, Mario Campone, et al.. (2014). Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Annals of Oncology. 25(12). 2357–2362. 407 indexed citations breakdown →

12.

Hortobágyi, Gabriel N., Martine Piccart, Hope S. Rugo, et al.. (2013). Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.. Journal of Clinical Oncology. 31(15_suppl). LBA509–LBA509. 59 indexed citations

13.

Shtivelband, Mikhail. (2013). Everolimus in hormone receptor–positive advanced breast cancer: Targeting receptor-based mechanisms of resistance. The Breast. 22(4). 405–410. 14 indexed citations

14.

Degtiar, Irina, Raji Pillai, Gerald A. Colvin, et al.. (2013). A prospective registry study assessing decision impact and patient outcomes following gene-expression profiling for tumor-site origin.. Journal of Clinical Oncology. 31(15_suppl). e22172–e22172. 1 indexed citations

15.

Campone, Mario, P. Fumoleau, Marta Gil-Martín, et al.. (2012). Abstract P6-11-08: A multicenter, open-label Ph IB/II study of BEZ235, an oral dual PI3K/mTOR inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer. Cancer Research. 72(24_Supplement). P6–11. 2 indexed citations

16.

Chalasani, Pavani, Mikhail Shtivelband, & Lee D. Cranmer. (2009). Advanced desmoplastic small round cell tumor: near complete response with trastuzumab-based chemotherapy.. PubMed. 7(7). 473–5. 2 indexed citations

17.

Cieslik, Katarzyna A., Ying Zhu, Mikhail Shtivelband, & Kenneth K. Wu. (2005). Inhibition of p90 Ribosomal S6 Kinase-mediated CCAAT/Enhancer-binding Protein β Activation and Cyclooxygenase-2 Expression by Salicylate. Journal of Biological Chemistry. 280(18). 18411–18417. 25 indexed citations

18.

McGary, Eric C., Amir Onn, Lisa Mills, et al.. (2004). Imatinib Mesylate Inhibits Platelet-Derived Growth Factor Receptor Phosphorylation of Melanoma Cells But Does Not Affect Tumorigenicity In Vivo. Journal of Investigative Dermatology. 122(2). 400–405. 47 indexed citations

19.

Shtivelband, Mikhail, et al.. (2003). Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression. Journal of Thrombosis and Haemostasis. 1(10). 2225–2233. 36 indexed citations

20.

Deng, Wuguo, Michael A. Saunders, Derek W. Gilroy, et al.. (2002). Purification and characterization of a cyclooxygenase‐2 and angiogenesis suppressing factor produced by human fibroblasts. The FASEB Journal. 16(10). 1286–1288. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact